Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tislelizumab

tislelizumab

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tislelizumab

36 trials tracked of tislelizumab: 10 in phase 3 or 4 and 10 with published results. The most-cited published study has 407 citations.

36Trials tracked
10Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 3 10 Phase 2 22 Phase 1 4
  1. Phase 3 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Completed · 407 cited
  2. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 326 cited
  3. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 319 cited
  4. Phase 3 A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer Completed · 289 cited
  5. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 261 cited
  6. Phase 3 Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Completed · 226 cited
Show 30 more trials
  1. Phase 3 Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 154 cited
  2. Phase 3 Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) Completed · 113 cited
  3. Phase 3 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma Completed · 73 cited
  4. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 9 cited
  5. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  6. Phase 2 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Completed
  7. Phase 2 Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Completed
  8. Phase 2 A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer Completed
  9. Phase 2 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed
  10. Phase 2 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed
  11. Phase 2 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors Completed
  12. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  13. Phase 2 Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer Completed
  14. Phase 2 Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody Completed
  15. Phase 2 Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer Completed
  16. Phase 2 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors Completed
  17. Phase 2 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer Completed
  18. Phase 2 Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Completed
  19. Phase 2 Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors Completed
  20. Phase 2 Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Completed
  21. Phase 2 A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC Completed
  22. Phase 2 Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Completed
  23. Phase 2 A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma Completed
  24. Phase 2 Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Completed
  25. Phase 2 AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer Completed
  26. Phase 2 Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma Completed
  27. Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed
  28. Phase 1 Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Completed
  29. Phase 1 A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors Completed
  30. Phase 1 Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Pulmonology & Critical Care Phase II
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Apr 6, 2026
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
Pulmonology & Critical Care Phase II
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Apr 6, 2026
Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
Pulmonology & Critical Care RCT
Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC Tislelizumab with chemotherapy before surgery improves survival in Chinese lung cancer patients
In a phase III RCT of 453 Chinese adults with resectable stage II-IIIA NSCLC, perioperative tislelizumab plus neoadjuvant chemotherapy signi…
Adding tislelizumab to chemotherapy before surgery helped Chinese lung cancer patients live longer, with a 79.3% three-year survival rate ve…
Apr 2, 2026